SynPlexity
Transforming synthetic biology with precise, cost-effective gene libraries.
Eugene, United States · Founded 2024
- Headquarters
- Eugene, Oregon
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- synplexity.com
- Last Round
- Pre-SeedJan 2024
- Rounds
- 1
About
SynPlexity enables researchers to scale biology with multiplexed DNA libraries — delivering more variants, faster discovery, and lower cost using proprietary DropSynth microreactor technology. The platform serves protein engineering, drug discovery, and functional genomics workflows, providing gene libraries up to 25,000+ fragments with in-house NGS quality control.
Summary
SynPlexity is an Artificial Intelligence company based in Eugene, United States, founded in 2024. Its most recent funding was a Pre-Seed round in Jan 2024. Investors include Portland Seed Fund and SOSV.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2024
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...